Literature DB >> 33396945

Remodeling Lipids in the Transition from Chronic Liver Disease to Hepatocellular Carcinoma.

Israa T Ismail1,2, Ashraf Elfert1, Marwa Helal1, Ibrahim Salama1, Hala El-Said1, Oliver Fiehn2.   

Abstract

Hepatocellular carcinoma (HCC) is a worldwide health problem. HCC patients show a 50% mortality within two years of diagnosis. To better understand the molecular pathogenesis at the level of lipid metabolism, untargeted UPLC MS-QTOF lipidomics data were acquired from resected human HCC tissues and their paired nontumor hepatic tissues (n = 46). Blood samples of the same HCC subjects (n = 23) were compared to chronic liver disease (CLD) (n = 15) and healthy control (n = 15) blood samples. The participants were recruited from the National Liver Institute in Egypt. The lipidomics data yielded 604 identified lipids that were divided into six super classes. Five-hundred and twenty-four blood lipids were found as significantly differentiated (p < 0.05 and qFDR p < 0.1) between the three study groups. In the blood of CLD patients compared to healthy control subjects, almost all lipid classes were significantly upregulated. In CLD patients, triacylglycerides were found as the most significantly upregulated lipid class at qFDR p = 1.3 × 10-56, followed by phosphatidylcholines at qFDR p = 3.3 × 10-51 and plasmalogens at qFDR p = 1.8 × 10-46. In contrast, almost all blood lipids were significantly downregulated in HCC patients compared to CLD patients, and in HCC tissues compared to nontumor hepatic tissues. Ceramides were found as the most significant lipid class (qFDR p = 1 × 10-14) followed by phosphatidylglycerols (qFDR p = 3 × 10-9), phosphatidylcholines and plasmalogens. Despite these major differences, there were also common trends in the transitions between healthy controls, CLD and HCC patients. In blood, several mostly saturated triacylglycerides showed a continued increase in the trajectory towards HCC, accompanied by reduced levels of saturated free fatty acids and saturated lysophospatidylcholines. In contrast, the largest overlaps of lipid alterations that were found in both HCC tissue and blood comparisons were decreased levels of phosphatidylglycerols and sphingolipids. This study highlights the specific impact of HCC tumors on the circulating lipids. Such data may be used to target lipid metabolism for prevention, early detection and treatment of HCC in the background of viral-related CLD etiology.

Entities:  

Keywords:  cirrhosis; desaturase; lipoproteins; palmitate; polyunsaturated fatty acids

Year:  2020        PMID: 33396945     DOI: 10.3390/cancers13010088

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  9 in total

1.  Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice.

Authors:  Elisabeth M Haberl; Rebekka Pohl; Lisa Rein-Fischboeck; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Christa Buechler
Journal:  Lipids Health Dis       Date:  2021-10-10       Impact factor: 3.876

2.  Intestinal Microbiota Remodeling Protects Mice from Western Diet-Induced Brain Inflammation and Cognitive Decline.

Authors:  Prasant Kumar Jena; Tahereh Setayesh; Lili Sheng; Jacopo Di Lucente; Lee Way Jin; Yu-Jui Yvonne Wan
Journal:  Cells       Date:  2022-02-01       Impact factor: 6.600

3.  Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma.

Authors:  Qingqing Wang; Yexiong Tan; Tianyi Jiang; Xiaolin Wang; Qi Li; Yanli Li; Liwei Dong; Xinyu Liu; Guowang Xu
Journal:  Cells       Date:  2022-03-22       Impact factor: 6.600

4.  Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis.

Authors:  Iuliana Nenu; Horia Stefanescu; Bogdan Procopet; Zeno Sparchez; Iulia Minciuna; Tudor Mocan; Daniel Leucuta; Corina Morar; Mircea Grigorescu; Gabriela Adriana Filip; Carmen Socaciu
Journal:  J Clin Med       Date:  2022-02-26       Impact factor: 4.241

5.  Identification of novel lipid biomarkers in xmrk- and Myc-induced models of hepatocellular carcinoma in zebrafish.

Authors:  Jerry D Monroe; Daniel Fraher; Xiaoqian Huang; Natalie A Mellett; Peter J Meikle; Andrew J Sinclair; Seth T Lirette; Nita J Maihle; Zhiyuan Gong; Yann Gibert
Journal:  Cancer Metab       Date:  2022-04-04

6.  Laboratory Profile of COVID-19 Patients with Hepatitis C-Related Liver Cirrhosis.

Authors:  Bianca Cerbu; Mirela Loredana Grigoras; Felix Bratosin; Iulia Bogdan; Cosmin Citu; Adrian Vasile Bota; Madalina Timircan; Melania Lavinia Bratu; Mihaela Codrina Levai; Iosif Marincu
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

Review 7.  Lipid alterations in chronic liver disease and liver cancer.

Authors:  Bichitra Paul; Monika Lewinska; Jesper B Andersen
Journal:  JHEP Rep       Date:  2022-03-26

Review 8.  The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update.

Authors:  Aleksandra Hliwa; Bruno Ramos-Molina; Dariusz Laski; Adriana Mika; Tomasz Sledzinski
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

9.  Inhibition of Ganglioside Synthesis Suppressed Liver Cancer Cell Proliferation through Targeting Kinetochore Metaphase Signaling.

Authors:  Ting Su; Xian-Yang Qin; Naoshi Dohmae; Feifei Wei; Yutaka Furutani; Soichi Kojima; Wenkui Yu
Journal:  Metabolites       Date:  2021-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.